ClinicalTrials.gg
CompletedNCT01722045RE-VIEWUpdated Dec 22, 2017Results posted

Study to Assess Best Corrected Visual Acuity (BCVA) in Patients With Neovascular Age-Related Macular Degeneration (AMD) Who Are Administered VEGF Trap-Eye (Intravitreal Aflibercept Injection)

A Phase 4 interventional study of Intravitreal Aflibercept Injection (IAI) in Age - Related Macular Degeneration (AMD), sponsored by Regeneron Pharmaceuticals. Completed at 49 sites in United States. Open to participants aged 50 Years and older. Per ClinicalTrials.gov, last updated 2017-12-22.

Sponsored by Regeneron Pharmaceuticals · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
154
Allocation
Not applicable
Ages
50 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 66 studies testing aflibercept in Macular Degeneration — 2 open to participants now, 5 under way, 2 of them phase 3. aflibercept · Macular Degeneration.

Enrollment
21st of 66
154 · median 55
Started
2012
with 4 others
Phase 4
27 of 66
none open now
Registered
11th of 66
by date
Lead sponsor
10 of 66
Regeneron Pharmaceuticals

Among the 66 studies testing aflibercept in Macular Degeneration, this one is the 21st largest by enrollment, is one of 5 that started in 2012, is one of 27 in phase 4, and was the 11th registered.

Macular Degeneration

1,459 studies on the registry are indexed under Macular Degeneration; 236 are open to participants now.

Browse Macular Degeneration studies →

Open to participants now

2 of the 66 studies testing aflibercept in Macular Degeneration are open now, in 9 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

About aflibercept

aflibercept: first FDA approval 2011 (EYLEA), first EMA approval 2012. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 166 Macular Degeneration studies recruiting now, 117 (70%) set no upper age limit and 5 (3%) stop at 75 or younger; 19 take children under 18; 35 take healthy volunteers.

This study: 50 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 66 studies testing aflibercept in Macular Degeneration, or all of them as a file.
02

Study summary

This is a phase 4, open-label, single arm, multicenter, clinical study in patients with neovascular AMD designed to evaluate the efficacy and safety of Intravitreal Aflibercept Injection (IAI) administered over 2 years , and to provide clinical information from the first year in the trial evaluating the adverse effects, if any, on the corneal endothelium following administration of IAI.

03

Conditions studied

  • Age - Related Macular Degeneration (AMD)

Keywords

  • AMD
04

Who can participate

Ages eligible
50 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Men or women great than or equal to 50 years of age with unilateral neovascular AMD
  2. BCVA ETDRS letter score of 73 to 24 (20/40 to 20/320) in the study eye
  3. Active primary subfoveal choroidal neovascularization (CNV) lesions secondary to AMD, including juxtafoveal lesions that affect the fovea as evidenced by FA in the study eye
  4. The CNV area must be at least 50% of total lesion size
  5. Willing and able to comply with clinic visits and study-related procedures
  6. Provide signed
  7. Provide signed Health Insurance Portability and Accountability Act (HIPAA) authorization

Exclusion criteria

Exclusion criteria include but are not limited to:

  1. Neovascular AMD in the fellow eye
  2. Corneal endothelial measures as judged by an independent reading center
  3. Any prior use of intraocular anti-VEGF treatment for neovascular AMD in either eye
  4. Structural damage to the center of the macula in the study eye that is likely to preclude improvement in BCVA following the resolution of macular edema
  5. History of cataract surgery, or other intraocular surgery in either eye, within 1 year of screening
  6. History of cataract surgery, or other intraocular surgery in either eye, within 1 year of screening, or yttrium aluminum garnet (YAG) Capsulotomy within 3 months of screening
  7. Contact lens wear in either eye within 6 months of screening
  8. History of angle closure glaucoma in either eye
  9. Intraocular laser therapy including selective laser trabeculoplasty (SLT), YAG, prophylactic peripheral iridotomy (PI) in either eye within 1 year of screening, or YAG Capsulotomy within 3 months of screening
  10. History of cataract surgery requiring an anterior chamber intraocular lens implant at any time in either eye
  11. Any prior ocular trauma (blunt or penetrating) in either eye
  12. Embedded corneal foreign body in either eye
  13. Evidence of infectious blepharitis, keratitis, scleritis, or conjunctivitis in either eye
  14. Ocular media of insufficient quality to obtain fundus and OCT images in the study eye
  15. Any prior ocular inflammation/infection in either eye within 3 months of the screening visit
  16. Any prior use of amantadine
  17. Significant pre-retinal fibrosis involving the macula in the study eye (where, in the opinion of the investigator, the pre-retinal fibrosis is causing distortion or traction on the central macular region which may be limiting vision, or inducing retinal edema/thickening, beyond that due to underlying CNV)
  18. Intraocular pressure (IOP) greater than or equal to 30 mm Hg in the study eye at screening
  19. Uncontrolled diabetes mellitus (DM) ( ≥8)
  20. Current treatment with systemic anti-VEGF therapeutics at screening
  21. Known serious allergy to the fluorescein sodium for injection in angiography
  22. Participation in an study within 30 days prior to the screening visit that involved treatment with any drug (excluding vitamins and minerals) or device.
  23. Positive serum hCG pregnancy test at the screening visit
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
154 participants (actual)

Study arms

  • Experimental
    Open label IAI

    Drug: Intravitreal Aflibercept Injection (IAI)

06

What researchers measure

Primary outcomes

  1. Change in Early Treatment Diabetic Retinopathy Study (ETDRS) Letter Score From Baseline to Week 100 - Last Observation Carried Forward (LOCF)

    Visual function of the study eye was assessed at a distance of 4 meters at every study visit using the Early Treatment Diabetic Retinopathy Study (ETDRS) Best Corrected Visual Acuity (BCVA) letter score. A higher score represents better vision. LOCF approach was used if any ETDRS letter score was missed after start of treatment, but baseline data were not carried forward. No formal statistical analyses were performed.

    Time frame: Baseline to Week 100

Secondary outcomes

  1. Percentage of Participants Whose Optical Coherence Tomography (OCT) Status Was "Dry" at Week 52 and at Week 100 (LOCF)

    Retinal fluid status was evaluated using spectral domain OCT on the study eye at every study visit. Last observation carried forward (LOCF) method was used to impute missing data.

    Time frame: Baseline to Week 100

  2. Percentage of Participants Who Gained ≥15 ETDRS Letters Compared With Baseline at Week 52 and Week 100 (LOCF)

    Visual function of the study eye was assessed at a distance of 4 meters at every study visit using the Early Treatment Diabetic Retinopathy Study (ETDRS) Best Corrected Visual Acuity (BCVA) letter score. A higher score represents better vision. LOCF approach was used if any ETDRS letter score was missed after start of treatment, but baseline data were not carried forward. No formal statistical analyses were performed.

    Time frame: At week 52 and At week 100

  3. Change From Baseline in Best Corrected Visual Acuity Score Through Week 52 (LOCF)

    Visual function of the study eye was assessed at a distance of 4 meters at every study visit using the Early Treatment Diabetic Retinopathy Study (ETDRS) Best Corrected Visual Acuity (BCVA) letter score. A higher score represents better vision.

    Time frame: Baseline to Week 52

  4. Percentage of Participants Who Gained ≥0, ≥5, ≥10, or ≥30 Letters From Baseline in BCVA Through Week 100 (LOCF)

    Visual function of the study eye was assessed at a distance of 4 meters at every study visit using the Early Treatment Diabetic Retinopathy Study (ETDRS) Best Corrected Visual Acuity (BCVA) letter score. A higher score represents better functioning.

    Time frame: Baseline to Week 100

  5. Percentage of Patients Who Lost >0, ≥5, ≥10, or ≥15 Letters From Baseline in BCVA Through Week 100 (LOCF)

    Visual function of the study eye was assessed at a distance of 4 meters at every study visit using the Early Treatment Diabetic Retinopathy Study (ETDRS) Best Corrected Visual Acuity (BCVA) letter score. A higher score represents better functioning.

    Time frame: Baseline to Week 100

Other outcomes

  1. Percent Change From Baseline in Corneal Endothelial Cell Density (ECD) at Week 24 and Week 52 in the Study Eye and the Fellow Eye - Endothelial Cell Density Evaluable Set (EES)

    EES included all eligible patients who were treated in the study eye, untreated in the fellow eye, had baseline specular microscopy image in both eyes, and completed week 52 evaluation in both eyes and treatment with systemic anti-VEGF therapeutics

    Time frame: At week 24 and At week 52

07

Results

Posted Dec 22, 2017

Participant flow

The study was conducted at 43 sites in the US from 14Nov2012 to 03Sep2015. The target study population consisted of men and women 50 years of age and older with neovascular AMD who met all study eligibility criteria. A total of 288 patients were screened, of whom 154 patients were enrolled and treated. A total of 126 patients completed week 100.

Participant flow — Overall Study
MilestoneOpen Label IAI
Started154
Completed126
Not completed28
Withdrew: Adverse event8
Withdrew: Death3
Withdrew: Withdrawal by subject8
Withdrew: Lost to follow-up4
Withdrew: Protocol deviation1
Withdrew: Physician decision3
Withdrew: Relocation (did not wish to transfer)1

Outcome measures

PrimaryChange in Early Treatment Diabetic Retinopathy Study (ETDRS) Letter Score From Baseline to Week 100 - Last Observation Carried Forward (LOCF)

Visual function of the study eye was assessed at a distance of 4 meters at every study visit using the Early Treatment Diabetic Retinopathy Study (ETDRS) Best Corrected Visual Acuity (BCVA) letter score. A higher score represents better vision. LOCF approach was used if any ETDRS letter score was missed after start of treatment, but baseline data were not carried forward. No formal statistical analyses were performed.

Time frame:
Baseline to Week 100
Reported as:
Mean · letters correctly read
Change in Early Treatment Diabetic Retinopathy Study (ETDRS) Letter Score From Baseline to Week 100 - Last Observation Carried Forward (LOCF)
letters correctly readOpen Label IAI
Week 10058.7 ± 20.5
Change from Baseline at Week 1004.5 ± 17.2
SecondaryPercentage of Participants Whose Optical Coherence Tomography (OCT) Status Was "Dry" at Week 52 and at Week 100 (LOCF)

Retinal fluid status was evaluated using spectral domain OCT on the study eye at every study visit. Last observation carried forward (LOCF) method was used to impute missing data.

Time frame:
Baseline to Week 100
Reported as:
Number · percentage of participants
Percentage of Participants Whose Optical Coherence Tomography (OCT) Status Was "Dry" at Week 52 and at Week 100 (LOCF)
percentage of participantsOpen Label IAI
Baseline: Dry0.7
Baseline: Not Dry99.3
Week 52: Dry53.0
Week 52: Not Dry47.0
Week 100: Dry51.7
Week 100: Not Dry48.3
SecondaryPercentage of Participants Who Gained ≥15 ETDRS Letters Compared With Baseline at Week 52 and Week 100 (LOCF)

Visual function of the study eye was assessed at a distance of 4 meters at every study visit using the Early Treatment Diabetic Retinopathy Study (ETDRS) Best Corrected Visual Acuity (BCVA) letter score. A higher score represents better vision. LOCF approach was used if any ETDRS letter score was missed after start of treatment, but baseline data were not carried forward. No formal statistical analyses were performed.

Time frame:
At week 52 and At week 100
Reported as:
Number · percentage of participants
Percentage of Participants Who Gained ≥15 ETDRS Letters Compared With Baseline at Week 52 and Week 100 (LOCF)
percentage of participantsOpen Label IAI
At week 5225.8
At week 10022.5
SecondaryChange From Baseline in Best Corrected Visual Acuity Score Through Week 52 (LOCF)

Visual function of the study eye was assessed at a distance of 4 meters at every study visit using the Early Treatment Diabetic Retinopathy Study (ETDRS) Best Corrected Visual Acuity (BCVA) letter score. A higher score represents better vision.

Time frame:
Baseline to Week 52
Reported as:
Mean · Letters correctly read
Change From Baseline in Best Corrected Visual Acuity Score Through Week 52 (LOCF)
Letters correctly readOpen Label IAI
At Week 5260.1 ± 18.94
Change from Baseline at Week 525.9 ± 15.54
SecondaryPercentage of Participants Who Gained ≥0, ≥5, ≥10, or ≥30 Letters From Baseline in BCVA Through Week 100 (LOCF)

Visual function of the study eye was assessed at a distance of 4 meters at every study visit using the Early Treatment Diabetic Retinopathy Study (ETDRS) Best Corrected Visual Acuity (BCVA) letter score. A higher score represents better functioning.

Time frame:
Baseline to Week 100
Reported as:
Number · percentage of participants
Percentage of Participants Who Gained ≥0, ≥5, ≥10, or ≥30 Letters From Baseline in BCVA Through Week 100 (LOCF)
percentage of participantsOpen Label IAI
Gained ≥ 0 Letters at Week 10070.9
Gained ≥ 5 Letters at Week 10057.6
Gained ≥10 Letters at Week 10040.4
Gained ≥30 Letters at Week 1004.6
SecondaryPercentage of Patients Who Lost >0, ≥5, ≥10, or ≥15 Letters From Baseline in BCVA Through Week 100 (LOCF)

Visual function of the study eye was assessed at a distance of 4 meters at every study visit using the Early Treatment Diabetic Retinopathy Study (ETDRS) Best Corrected Visual Acuity (BCVA) letter score. A higher score represents better functioning.

Time frame:
Baseline to Week 100
Reported as:
Number · percentage of participants
Percentage of Patients Who Lost >0, ≥5, ≥10, or ≥15 Letters From Baseline in BCVA Through Week 100 (LOCF)
percentage of participantsOpen Label IAI
Lost >0 Letters at Week 10029.1
Lost ≥5 Letters at Week 10023.2
Lost ≥10 Letters at Week 10016.6
Lost ≥15 Letters at Week 10013.2
Other pre-specifiedPercent Change From Baseline in Corneal Endothelial Cell Density (ECD) at Week 24 and Week 52 in the Study Eye and the Fellow Eye - Endothelial Cell Density Evaluable Set (EES)

EES included all eligible patients who were treated in the study eye, untreated in the fellow eye, had baseline specular microscopy image in both eyes, and completed week 52 evaluation in both eyes and treatment with systemic anti-VEGF therapeutics

Time frame:
At week 24 and At week 52
Reported as:
Mean · percent change from baseline
Percent Change From Baseline in Corneal Endothelial Cell Density (ECD) at Week 24 and Week 52 in the Study Eye and the Fellow Eye - Endothelial Cell Density Evaluable Set (EES)
percent change from baselineOpen Label IAI
Week 24: Study eye-0.3 ± 4.15
Week 24: Fellow eye1.0 ± 4.28
Week 52: Study eye-0.2 ± 4.19
Week 52: Fellow eye-0.3 ± 4.04

Adverse events

Collected over Adverse event data were collected during the period baseline to week 100. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Open Label IAI—45/154 (29.2%)38/154 (24.7%)
Most frequent serious events
Showing 10 of 67
Most frequent serious events
EventOpen Label IAI
Cardiac failure congestiveCardiac disorders4/154
Squamous cell carcinoma of skinNeoplasms benign, malignant and unspecified (incl cysts and polyps)3/154
Atrial fibrillationCardiac disorders3/154
Coronary artery diseaseCardiac disorders3/154
PneumoniaInfections and infestations3/154
Acute myocardial infarctionCardiac disorders2/154
Myocardial infarctionCardiac disorders2/154
CellulitisInfections and infestations2/154
SyncopeNervous system disorders2/154
Autoimmune haemolytic anaemiaBlood and lymphatic system disorders1/154
Most frequent other events
Most frequent other events
EventOpen Label IAI
Neovascular age-related macular degenerationEye disorders20/154
HypertensionVascular disorders13/154
Conjunctival haemorrhageEye disorders12/154
Urinary tract infectionInfections and infestations12/154
BronchitisInfections and infestations10/154
Vitreous detachmentEye disorders9/154
Vitreous floatersEye disorders9/154
NasopharyngitisInfections and infestations9/154

Baseline characteristics

The baseline analysis population was based on the safety analysis set (SAF) and included all patients who received at least 1 dose of study drug, regardless of the treatment for the study eye or the fellow eye.

Age, Categorical
Age, Categorical(Participants)Open Label IAI
<=18 years0
Between 18 and 65 years17
>=65 years137
Sex: Female, Male
Sex: Female, Male(Participants)Open Label IAI
Female96
Male58
Best Corrected Visual Acuity (BCVA) in the study eye (Letters Read)
Best Corrected Visual Acuity (BCVA) in the study eye (Letters Read)(letters correctly read)Open Label IAI
Mean54.3 ± 13.47
Central Subfield Thickness in the study eye by Optical Coherence Tomography (OCT)
Central Subfield Thickness in the study eye by Optical Coherence Tomography (OCT)(micrometers (μm))Open Label IAI
Mean420.5 ± 134.90
Corneal Endothelial Cell Density - Endothelial Cell Density Evaluable Set (EES)
Corneal Endothelial Cell Density - Endothelial Cell Density Evaluable Set (EES)(cells/mm^2)Open Label IAI
Study eye2409.8 ± 363.89
Fellow eye2388.0 ± 383.93
08

Study locations

49 sites
  • Phoenix, Arizona, United States
  • Tucson, Arizona, United States
  • Beverly Hills, California, United States
  • Oakland, California, United States
  • Palm Desert, California, United States
  • Sacramento, California, United States
  • Santa Ana, California, United States
  • Westlake Village, California, United States
  • Colorado Springs, Colorado, United States
  • Golden, Colorado, United States
  • Boynton Beach, Florida, United States
  • Fort Lauderdale, Florida, United States
  • Fort Myers, Florida, United States
  • Pensacola, Florida, United States
  • Plantation, Florida, United States
  • Tampa, Florida, United States
  • Winter Haven, Florida, United States
  • Augusta, Georgia, United States
  • Oak Park, Illinois, United States
  • New Albany, Indiana, United States
  • Wichita, Kansas, United States
  • Lexington, Kentucky, United States
  • Boston, Massachusetts, United States
  • Worcester, Massachusetts, United States
  • Jackson, Michigan, United States
  • Lincoln, Nebraska, United States
  • Las Vegas, Nevada, United States
  • Portsmouth, New Hampshire, United States
  • Bloomfield, New Jersey, United States
  • Lawrenceville, New Jersey, United States
  • Northfield, New Jersey, United States
  • Teaneck, New Jersey, United States
  • Rochester, New York, United States
  • Asheville, North Carolina, United States
  • Oklahoma City, Oklahoma, United States
  • Portland, Oregon, United States
  • Salem, Oregon, United States
  • Kingston, Pennsylvania, United States
  • Pittsburgh, Pennsylvania, United States
  • Florence, South Carolina, United States
  • Ladson, South Carolina, United States
  • West Columbia, South Carolina, United States
  • Rapid City, South Dakota, United States
  • Nashville, Tennessee, United States
  • Arlington, Texas, United States
  • Fort Worth, Texas, United States
  • Houston, Texas, United States
  • San Antonio, Texas, United States
  • Seattle, Washington, United States
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Nov 2012, a primary completion of Sep 2015 and a completion of Sep 2015. It does not say whether these dates are actual or estimated.

Results were first posted in Dec 2017, 2 years 3 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 2, 2012
First posted
Nov 6, 2012
Start
Nov 2012
Primary completionActual
Sep 2015
CompletionActual
Sep 2015
Results first posted
Dec 22, 2017
Last update
Dec 22, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 22, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01722045
Responsible party
Sponsor
First posted
Nov 6, 2012
Start date
Nov 2012
Primary completion
Sep 2015
Completion
Sep 2015
Results posted
Dec 22, 2017
Last update
Dec 22, 2017

Study contacts

Clinical Trial Management
study director · Regeneron Pharmaceuticals

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Aflibercept

Start the discussion